Do you have depression?
Are you interested in a new potential treatment?
Kardinia Health is supporting a new treatment trial for depression run by Barwon Health and Deakin University.
The Aim
There is evidence from basic science and human studies that candesartan may have anti-depressant properties. The Deakin University led trial aims to assess if this commonly prescribed and well tolerated blood pressure medication, candesartan, may help people with major depressive disorder or bipolar disorder.
The trial aims to test if candesartan 16mg a day, in addition to usual treatment, helps to reduce symptoms of depression and improve general quality of life.
The Reason
Depression may, in part, be caused by inflammation and oxidative stress in the brain. Candesartan may help to reduce this inflammation and oxidative stress and protect neurons against stress. Candesartan may therefore be beneficial in reducing symptoms of depression.
Key Points for Participation
- There will be no costs involved to be on the trial
- Participants can continue on their usual treatments as long as there are no known interactions with candesartan.
- The trial will last for 16 weeks
- Study visits at a research site will be required every 2 to 4 weeks throughout the trial
- Participants will be randomly allocated to receive either the active medication – candesartan or placebo (an inactive substance that does not contain any candesartan).
- Safety will be monitored throughout the study by blood tests and blood pressure monitoring at study visits
- Once enrolled in the study, participants will receive reimbursement of travel expenses up to $20 at each visit completed.
If you would like to receive more information about the study that might contribute to reducing depression or enquire about participating, please ask your Kardinia Health GP or contact the CADET Trial team on:
Email: cadet-trial@deakin.edu.au
Phone: 0402 196 595
